Sunday 22 July 2018 - 18:12
In Business 38 Years - Since 1980
Doxorubicin and Venetoclax Are Now Back in Stock -- July 5, 2018
FREE SHIPPING TO THE U.S. AND 33 OTHER COUNTRIES! [Read more].
Search:
A-4477 Alpelisib, Free Base, >99%
Synonyms : [BYL-719] [NVP-BYL719]
- Size
- US $
- €
- £
- ¥
- 5 mg
- 59
- 50
- 43
- 6,500
- In stock
- 10 mg
- 83
- 70
- 61
- 9,200
- In stock
- 25 mg
- 113
- 95
- 83
- 12,500
- In stock
- 50 mg
- 144
- 122
- 106
- 15,900
- In stock
- 100 mg
- 232
- 196
- 171
- 25,600
- In stock
- 200 mg
- 397
- 336
- 293
- 43,800
- In stock
- 500 mg
- 878
- 744
- 648
- 96,800
- In stock
- 1 g
- 1,625
- 1,378
- 1,200
- 179,200
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 33 Other Countries
- M.W. 441.47
- C19H22F3N5O2S
- [1217486-61-7]
- Alpelisib, also known as BYL719, is a potent and selective phosphatidylinositol-3 kinase [alpha] inhibitor. It inhibited P110[alpha], p110[beta], p110[delta], and p110[gamma] with IC50 values of 5 nM, 1.2 µM, 0.29 µM and 0.25 µM, respectively, in biochemical assays. It inhibited the Akt phosphorylation with IC50 values of 74 nM in Rat1-myr-p110[alpha] cells, 2.2 µM in Rat1-myr-p110[beta] cells, and 1.2 µM in Rat1-myr-p110[delta] cells. Furet P., et al. "Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation." Bioorg. Med. Chem. Lett. 23: 3741-3748 (2013).
- Alpelisib showed dose- and time-dependent inhibition of PI3K[alpha] signaling in vivo and demonstrated robust anti-tumor response and tolerability in PIK3CA-dependent tumor models. Fritsch C., et al. "Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials." Mol. Cancer Ther. 13: 1117-1129 (2014).
- mTORC1 inhibition is necessary for sensitivity to PI3K p110[alpha] inhibition by alpelisib in PIK3CA-mutant breast cancer. Elkabets M., et al. "mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer." Sci. Transl. Med. 5: 196ra99 (2013).
- Related CAS numbers: 1584128-91-5 for the hydrochloride salt.
- Another CAS number previously assigned to BYL-719 free base, namely 1361185-44-5, has been deleted by CAS and is no longer in use.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
